35562 Federal Register / Vol. 87, No. 112 / Friday, June 10, 2022 / Notices 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; 

Collaborative Research at the NIH Clinical 

Center (U01). 

Date: July 7, 2022. 

Time: 1 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute at Shady 

Grove, 9609 Medical Center Drive, Room 

7W240, Rockville, Maryland 20850 (Virtual 

Meeting). 

Contact Person: Hasan Siddiqui, Ph.D., 

Scientific Review Officer, Special Review 

Branch, Division of Extramural Activities, 

National Cancer Institute, NIH 9609, Medical 

Center Drive, Room 7W240, Rockville, 

Maryland 20850, 240–276–5122, 

hasan.siddiqui@nih.gov. 

Name of Committee: National Cancer 

Institute Initial Review Group; Cancer 

Centers Study Section (A). 

Date: August 4, 2022. 

Time: 10:30 a.m. to 12 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute at Shady 

Grove, 9609 Medical Center Drive, Room 

7W530, Rockville, Maryland 20850 

(Telephone Conference Call). 

Contact Person: Shamala K. Srinivas, 

Ph.D., Associate Director, Office of Referral, 

Review, and Program Coordination, Division 

of Extramural Activities, National Cancer 

Institute, NIH 9609, Medical Center Drive, 

Room 7W530, Rockville, Maryland 20850, 

240–276–6442, ss537t@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: June 7, 2022. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–12589 Filed 6–9–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The invention listed below is 

owned by an agency of the U.S. 

Government and is available for 

licensing to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

FOR FURTHER INFORMATION CONTACT: 

Dawn Taylor-Mulneix at 301–767–5189, 

or dawn.taylor-mulneix@nih.gov. 

Licensing information may be obtained 

by communicating with the Technology 

Transfer and Intellectual Property 

Office, National Institute of Allergy and 

Infectious Diseases (NIAID), 5601 

Fishers Lane, Rockville, MD 20852; tel. 

301–496–2644. A signed Confidential 

Disclosure Agreement will be required 

to receive copies of unpublished 

information related to the invention. 

SUPPLEMENTARY INFORMATION: 

Technology description follows: 

Human lgA Monoclonal Antibody That 

Targets a Conserved Site on the 

Plasmodium Falciparum 

Circumsporozoite Protein 

Description of Technology 

Scientists at NIAID have isolated 

MAD2–6, an IgA antibody active against 

Plasmodium falciparum sporozoites, the 

infectious agent of malaria. In 2019, the 

majority of the 229 million cases 

resulted from P. falciparum infections. 

Because P. falciparum has a complex 

lifecycle during human infection, most 

advanced malaria vaccine candidates 

and current chemoprophylaxis drugs 

can confer only partial, short-term 

protection in malaria-endemic areas. 

Thus, the MAD2–6 antibody could be 

used alone or in combination with 

current technology. 

MAD2–6 binds to a unique epitope 

overlapping with region I, a functionally 

important region of the Plasmodium 

falciparum circumsporozoite protein 

(PfCSP). This binding site of PfCSP is a 

previously unknown target for 

protective antibodies, which may be 

useful as a new target. Monoclonal 

antibodies are promising tools for 

prevention of malaria and could replace 

or be combined with malaria 

chemoprevention in areas with seasonal 

malaria. 

This technology is available for 

licensing for commercial development 

in accordance with 35 U.S.C. 209 and 37 

CFR part 404, as well as for further 

development and evaluation under a 

research collaboration. 

Potential Commercial Applications 

• Alternate technologies are required 

to address drug resistance. 

• A multi-targeted approach can 

combat all stages of the parasite 

lifecycle. 

• Prophylactic treatment for 

neutralization of P. falciparum in 

normal or at-risk populations including 

pregnant women. 

Competitive Advantages 

• Antibodies can be effective as 

prophylactics, alone or in combination 

with other treatments. 

Development Stage 

• Pre-Clinical. 

Inventors: Joshua Tan Ph.D., Peter 

Crompton M.D., Robert Seder M.D., 

Hyeseon Cho Ph.D., all of NIAID. 

Publications: Tan, J., et al., 

‘‘Functional human IgA targets a 

conserved site on malaria sporozoites’’, 

Science Translational Medicine, Vol. 

13(599), 23 June 2021. https://doi.org/ 

10.1126/scitranslmed.abg2344. 

Intellectual Property: HHS Reference 

No. E–130–2020–0–PCT–02—PCT 

Application No. PCT/US2021/037571 

filed on 6 June 2021. 

Licensing Contact: To license this 

technology, please contact Dawn TaylorMulneix at 301–767–5189, or 

dawn.taylor-mulneix@nih.gov, and 

reference E–130–2020. 

Collaborative Research Opportunity: 

The National Institute of Allergy and 

Infectious Diseases is seeking statements 

of capability or interest from parties 

interested in collaborative research to 

further develop, evaluate or 

commercialize this technology. For 

collaboration opportunities, please 

contact Dawn Taylor-Mulneix at 301– 

767–5189, or dawn.taylor-mulneix@

nih.gov. 

Dated: June 3, 2022. 

Surekha Vathyam, 

Deputy Director, Technology Transfer and 

Intellectual Property Office, National Institute 

of Allergy and Infectious Diseases. 

[FR Doc. 2022–12482 Filed 6–9–22; 8:45 am] 

BILLING CODE 4140–01–P 


jspears on DSK121TN23PROD with NOTICES1